Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial ResultsGlobeNewsWire • 02/27/24
These 2 Healthcare Stocks Are in Nvidia's Portfolio. Should They Be in Yours?The Motley Fool • 02/22/24
Nvidia Just Invested in These 5 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch.The Motley Fool • 02/21/24
Why Did Nvidia Invest in These 5 Artificial Intelligence (AI) Stocks? Should You Buy Them, Too?The Motley Fool • 02/20/24
Analysts Estimate Recursion Pharmaceuticals (RXRX) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 02/19/24
Investors Are Piling Into Nvidia Stock. But Nvidia Is Investing in 5 Other AI Stocks.The Motley Fool • 02/19/24
Recursion Pharmaceuticals (RXRX) Surges 13.8%: Is This an Indication of Further Gains?Zacks Investment Research • 02/16/24
Nvidia dives deeper into AI drug development with Amgen, Recursion partnershipsMarket Watch • 01/08/24
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/08/24
Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 01/08/24
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery PipelineGlobeNewsWire • 01/04/24